Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796522 | 0.91 | PTGS2 (0.42) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL5558905 | 0.90 | PTGS2 (0.42) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL6424911 | 0.90 | AKR1C3 (0.45) | PTGS2MAPTTP53AKR1C3AKR1C2 | |
| SCHEMBL5554691 | 0.90 | PTGS2 (0.43) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL6423105 | 0.89 | PTGS2 (0.46) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL5554171 | 0.89 | AKR1C3 (0.52) | PTGS2CNR1CNR2MAPTAKR1C3 | |
| SCHEMBL5554674 | 0.89 | PTGS2 (0.43) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL5559062 | 0.89 | PTGS2 (0.46) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL5559076 | 0.89 | PTGS2 (0.51) | PTGS2CNR1CNR2MAPTTP53 | |
| SCHEMBL5559612 | 0.88 | PLA2G2A (0.49) | PTGS2CNR1CNR2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885CNR1 55/4885CNR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.